Rheumatology

Back to articles

Newly approved oral agent brings hope for psoriatic arthritis

KEY POINT

Use of apremilast (Otezia—Celgene), which was approved by FDA in March 2014, resulted in a significant improvement in the signs and symptoms of psoriatic arthritis, and increased physical functioning, according to results of the PALACE 1 trial.